retatrutide in spanish ESC 2024: improves lipid and cardiovascular risk profile Phase II trial RETATRUTIDE 10mg 20mg 30mg 40mg

PMID: 25823991

The FDA has no direct precedent for reviewing a glucagon agonist for chronic weight management

This weight regain is not due to medication "dependence" in the traditional sense, but rather reflects the underlying biology of obesity as a chronic condition

Okay, what happens if you can't make that gasoline from your crude oil hormone of levothyroxine

The peptide GLP-1 is produced by the enteroendocrine L-cells of the small intestine as a cleavage product of the pre-proglucagon gene within minutes in response to oral glucose or fat

Medicare does already cover GLP-1 for some non-weight-loss indications: Part D covers Ozempic and Mounjaro for type 2 diabetes, and Wegovy received a new indication for cardiovascular risk reduction in patients with established heart disease and obesity